These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10962217)

  • 1. Valproate metabolism during valproate-associated hepatotoxicity in a surviving adult patient.
    McLaughlin DB; Eadie MJ; Parker-Scott SL; Addison RS; Henderson RD; Hooper WD; Dickinson RG
    Epilepsy Res; 2000 Oct; 41(3):259-68. PubMed ID: 10962217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state dispositions of valproate and diflunisal alone and coadministered to healthy volunteers.
    Addison RS; Parker-Scott SL; Eadie MJ; Hooper WD; Dickinson RG
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):715-21. PubMed ID: 11214782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. I. Biochemical, histopathological and pharmacokinetic studies.
    Löscher W; Wahnschaffe U; Hönack D; Wittfoht W; Nau H
    Epilepsy Res; 1992 Dec; 13(3):187-98. PubMed ID: 1493781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproate metabolites and hepatotoxicity in an epileptic population.
    Tennison MB; Miles MV; Pollack GM; Thorn MD; Dupuis RE
    Epilepsia; 1988; 29(5):543-7. PubMed ID: 3137018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apparent autoinduction of valproate beta-oxidation in humans.
    McLaughlin DB; Andrews JA; Hooper WD; Cannell GR; Eadie MJ; Dickinson RG
    Br J Clin Pharmacol; 2000 May; 49(5):409-15. PubMed ID: 10792197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Children versus adults: pharmacokinetic and adverse-effect differences.
    Anderson GD
    Epilepsia; 2002; 43 Suppl 3():53-9. PubMed ID: 12060006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
    Kondo T; Kaneko S; Otani K; Ishida M; Hirano T; Fukushima Y; Muranaka H; Koide N; Yokoyama M
    Epilepsia; 1992; 33(1):172-7. PubMed ID: 1733753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S; Seo T; Hagiwara T; Ueda K; Yamauchi T; Nagata S; Ando Y; Ishitsu T; Nakagawa K
    J Pharm Pharmacol; 2008 Feb; 60(2):267-72. PubMed ID: 18237476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valproate-associated hepatotoxicity and its biochemical mechanisms.
    Eadie MJ; Hooper WD; Dickinson RG
    Med Toxicol Adverse Drug Exp; 1988; 3(2):85-106. PubMed ID: 3131628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. III. Influence of fasting.
    Löscher W; Wahnschaffe U; Hönack D; Drews E; Nau H
    Epilepsy Res; 1993 Dec; 16(3):183-94. PubMed ID: 8119269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.
    Fisher E; Siemes H; Pund R; Wittfoht W; Nau H
    Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication.
    Löscher W; Nau H; Wahnschaffe U; Hönack D; Rundfeldt C; Wittfoht W; Bojic U
    Epilepsy Res; 1993 Jun; 15(2):113-31. PubMed ID: 8370349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U
    Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolite profiles in patients on high-dose valproate monotherapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsy Res; 1996 Oct; 25(2):107-12. PubMed ID: 8884168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Valproate-associated hepatotoxicity--pathogenesis, clinical aspects, therapy and prevention].
    Siemes H; Nau H
    Klin Padiatr; 1991; 203(6):411-9. PubMed ID: 1758143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits.
    Yokogawa K; Iwashita S; Kubota A; Sasaki Y; Ishizaki J; Kawahara M; Matsushita R; Kimura K; Ichimura F; Miyamoto K
    Pharm Res; 2001 Sep; 18(9):1320-6. PubMed ID: 11683247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study.
    Lindberger M; Tomson T; Wallstedt L; Ståhle L
    Epilepsia; 2001 Feb; 42(2):256-61. PubMed ID: 11240599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding topiramate to valproate therapy may cause reversible hepatic failure.
    Bumb A; Diederich N; Beyenburg S
    Epileptic Disord; 2003 Sep; 5(3):157-9. PubMed ID: 14684351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.